Skip to main content
BEAM $20.90 -0.19%
BEAM logo
BEAM · Beam Therapeutics Inc.
Track BEAM — free
$20.90 -0.04 (-0.19%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20 3.89M Avg daily vol (3M) 2.05M
All webcasts

Conference · 2026-11-17

Beam Therapeutics Inc. (BEAM) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay Verified speakers
Nov 17, 2026 31:20 91 turns
Period
2026-11-17
Runtime
31:20
Sources
2 artifacts

Transcript & audio

Verified speakers 31:20 Audio
Michael Yee Other

Good afternoon, everyone. Thank you for joining us. I hope everyone had a great lunch here at the UBS Global Biopharma Conference. Michael Yee, Global Head of Biotech Research here at UBS, and really pleased to have up on stage with us Beam Therapeutics, Chief Executive Officer John Evans. Thank you so much for being here with us.

It's great to be here.

Michael Yee Other

Thank you. Fantastic. So Beam has had an exciting year. You've been reporting. A lot of data across not only your lead program, Sickle Cell, which just had an update, but also across the AAT program, and also some early data across GSD-1A, too. So let's talk about some of that. Maybe if I could just offer you an opportunity to make some opening comments, where are you with these three programs, and what are the next key milestones as you think about some of these key programs? Great.

Yeah, so thank you for having me again, and we are having a very exciting year. I think this is the year when the full potential of this platform that we've been building is now really visible, particularly the fact that it is a platform technology. This is base editing, where we're going to fix single letters in genes to correct for mutations, and it's delivery that is very well validated at this point, whether it be an X-Viva transplant or a lipid nanoparticle, and once those begin to work, they keep working. And we have every reason to believe that the next version of that technology, the next time we put it into patients' different disease, we should get the same positive result, and we're starting to see that now. So across those programs with sickle cell disease, as you noted, we just had the top-line data, just top-line release, but it's positive. So that's great. So that keeps us on track for a BLA filing as early as December. So we're hard at work right now on that. We talk a lot more about that, but very exciting, highly differentiated program for patients with sickle cell disease.

Speaker 2

You're hosting something at ASH, I think, too.

Yes. Yep. That's going to be a nice event. Yep, absolutely. Then with alpha-1, of course, very high-profile disease where we have a really significant leadership position. First time ever in medical history to actually correct a broken mutation back to normal and get these patients to what looks like it should be a functional cure. There, it's all about how fast we're going. We have an incredible global site network now, and we've announced that we started dosing in July. We will be finished dosing the 50 patients in that trial by the first half of next year. So it's moving really quickly. Then we follow them for a year, and then that's the data set that we can use to file. So that's really, really exciting. And then, as you noted, there's sort of a third leg of the stool for BEAM, which is our metabolic sort of profile franchise. We have a program on PKU that we'll be dosing in early 27. And then BIM-301 for glycogen storage disease 1A, we just had its first clinical proof of concept data, and here, really dramatic results showing in some of these patients, reduction of cornstarch utilization, and actually freedom from cornstarch in a couple of situations, and ability to fast. It's something that these patients just can't do without going hypoglycemic.

Michael Yee Other

It's basically a functional cure in an ultra-rare population.

Correct. So very, very exciting for that population. And then more broadly, it kind of speaks to what should be possible in PKU and in many other disorders of the liver where we should be able to now reliably deliver the base editor, reliably fix the mutation, and that really should be a functional cure for me.

Speaker 2

Might I add, the latter two programs are in vivo as well.

That's right. Yes, of all of those, the only one is ex vivo sickle, then obviously our LNP and mRNA capabilities are quite significant. So from alpha one through PKU and GSD, it's all in vivo, which means, you know, two to three hour infusion, and off you go.

Speaker 2

One and done in two to three hours. Let's start with sickle cell. I mean, it's important. You've got an ASH presentation and an event coming up. You reported the top line data, and all is very positive. And I think without, you know, comparing all the details, should be, in fact, comparable or better than the leading program from Kazjevi Vertex. And investors look at this and they go, I don't know, John, Vertex sales are X. They're not what the levels that they are, which people had a blockbuster indication just to be careful. They cover Vertex. They have a couple of different products. And of those couple of different products, they guided to $500 million for the year, but that's a couple of different products. So I think you can determine that Kazjevi is a fraction of that. We're certainly not at the billions that they thought, but the product's actually been on the market for two years now. So why should people think about your product, which is fairly similar to the Kazjevi product, to be better or get better utilization of commercial sales? Are there issues that Vertex has had that you think you can overcome?

Yes. So I'll make two arguments for you, one on the product and the differentiation we're going to bring, but then second, let's go back to the category, which I think is actually now worth looking at and turning on, as we predicted. So the product, you know, we do think it's a highly differentiated potential program. The data has been really striking, all the way from, of course, the hematology outcomes, where we're getting higher levels of hemoglobin F, which is the protective form, lower levels of sickle globin than has been reported by others. So we get to the 60-40 ratio, which is similar to patients who are not diseased. They just are carriers of the mutation. That is important for correcting blood outcomes. Second, because our edit is so gentle with the base editing, we believe, these patients are getting out of the hospital faster. So you're seeing time to neutrophil and engraftment, time to platelet engraftment, significantly faster than what has been seen before. And that means less exposure to toxicities when you're in the transplant phase and, of course, less hospital.

Speaker 2

Remind me, did you report out the VOE numbers?

So then that's the other piece. We have not reported that recently. I think to date, we have just said no investigator reported VOEs. So you'll see some of that start to get reported in some of our upcoming. Okay.

Michael Yee Other

We wouldn't expect that to be zero.

We wouldn't expect, no, no. But I think that's where it's harder to differentiate because, you know, Kastchev and Lifjenny are in the, you know, 89, 90% range. Nice. But I think we should be – our goal would be to be at least competitive with that, if not –

Speaker 2

Now, why I ask about some of the differentiation, appreciating that VOE, while the regulatory endpoint is going to be basically 90 percent, is that your team has explained that there are challenges in terms of what Vertex has had to go through in terms of getting patients, Yeah. Getting them through mobilization, getting them through manufacturing success, and then ultimately delivering the product to book the revenues. Yes. So that can be many, many, many months of work before getting the revenues, even though they say they have hundreds of patients ready to go. So what are those challenges, and then why do you think you would be better? It's less mobilization, and you have a 99% manufacturing because they're not at that level.

So, back to our differentiation. So, hematology, I think, is going to be best in class. The time and engraftment, potentially best in class. Then manufacturing and process, also potentially best in class. So, what we've seen just in the Beacon trial, okay, is we are running significantly faster than our competitors. So, Kaschevi, what has been reported and what we've heard is it can be anywhere from 9 to 12 months to get through the whole process. That's consistent with the slow revenue curve that we've seen. Livjenia, a little faster, but still, you know, it can be long and uncertain. For us, our median time from the start of mobilization, the first time the patient shows up to get their blood collected, to when they are dosed is 4 1⁄2 months. Okay, that is significantly faster. Two-thirds of patients are getting away with just one.

Michael Yee Other

Your 9 to 12 was sort of comparing what you're hearing in the real world.

Well, and what was seen in the trial, I think.

Speaker 2

Okay, and you're telling me you can be four and a half months. Now, I understand that one or two of those months are basically less mobilization cycles. Okay, what are the other few months?

Yeah, so less mobilization cycles is a big deal. We have our own internal manufacturing facility, which is not true in the field. That allows us to schedule much more compactly. We have our own quality release, right? So you're not sending this out to a bunch of different vendors around the world to check things off. It's all done internally, and then it gets back. And then also our yield, because the base editing is very strong. So we don't need as many cells to get to the same dose outcome.

Michael Yee Other

Okay, okay.

So all of that adds up, and it makes a big difference. We also, I think, just have the benefit, frankly, of going third here, where we've been able to build on what the field knows, and our process is highly automated, highly streamlined in a way that just hasn't been done yet. Okay. So I feel confident that we have a potentially differentiated product that can add meaningfully to this category, but now let me go back to the category, because I think we have predicted this. I think what I said to you even maybe last year was there's clearly demand for these patients. The problem has been manufacturing and getting it to them. So just yesterday, Genetics came out with a press release, and they talked about Lifigenia. This is the other product in the category. So Lifigenia is a complicated product. It's a lentivirus, but they have been, I think, more successful in delivering to patients. So they have already this year booked over $300 million of sales. They're on track to hit $500 million for the annual year this year in the U.S. with Libgenia. And the company is profitable. Okay, so they are able to do this at a cost that is reasonable within those. So the category of Lifgenia plus Casjevi, I agree Vertex doesn't fully split out their numbers, but that category.

Michael Yee Other

Yeah, Vertex probably does like $200 million.

I'm an analyst. That would have been my guess.

Michael Yee Other

$200 million, you're telling me they're doing three fits.

So the category between those two products this year, okay, is on track to be over $700 million. And that's in year 2-3. So this is ramping just the way we would have guessed. We've always said this is not for every patient, but for the 10% of patients who are really sick, this is the right choice, and that's 10,000 people.

Speaker 2

We agree. Even for the patients that would be amenable to this, obviously analysts have built their estimates, not on all sickle cell patients, but the people that would need this product, that that is 10,000 patients, that is multi-billions and billions of dollars, and you believe that when this product launches, you will have met the manufacturing criteria, the speed, and that's going to be a differentiation. Because you only get to pick one. That's right. And that will be a big difference. Plus, they've grown the market. They've gotten insurance. These other people have sort of built, paved the road for you. That's right. A lot of those things have been sorted out.

And given this extent of the demand, we are thrilled there's other products available. Like this is a category that's very important to these sites and these patients. But I do think there's a lot of specific demand for what we can bring with our profile.

Michael Yee Other

So you think you can beat the launch of Vertex?

I think, stay tuned. I think, I mean, I think at the very least, if the manufacturing process that we can deliver commercially is similar to what we've done in Beacon, then we should do better. Why would it not be?

Michael Yee Other

It's the same manufacturing site. Now, you're not doing 100 patients. We're going to be scaling up to do a lot more.

Yeah, it scales, but I think what you just put your finger on is actually quite important, which is this is the same site. So it's really the way, I mean, we did Beacon, we enrolled and dosed 50 patients of Beacon in about a year. All right. So we have to scale that up, but not by 10x immediately. So this should be very doable.

Speaker 2

All right. I hear a potential better launch on a low expectation basis, to be fair.

No, I think this is an area that investors are, it's kind of time for them to lean in and learn more about it. Because I think it's happening, and it's happening in just the way I would have guessed. And it's perfect timing because we're coming.

Speaker 2

There's a reasonable explanation for it because people have a sort of a view about what it is, but you're saying there's.

Well, and LiftGenia, to be fair, is private, right? You know, the old Bluebird was bought by Carlisle. So all that is happening outside of the view of the public market. I think now they're starting to be more clear about their numbers, and obviously I think that's going to be helpful to people to understand where the category is.

Speaker 2

So the second program, obviously, there's been a lot of focus around this. It's a different market, and this is alpha-1 antitrypsin, AAT, a potential to offer people essentially a functional cure here, and you've dosed a lot of patients, and you've shown, I'm going to throw out a number, north of 15 or so micromolar, and on one side, that is clear proof of concept, good safety. Maybe 15 is above a general level where people think that should be carrier-like and should be generally a functional cure, and you're enrolling a pivotal study, and you just told me you're going to complete enrollment by the first half of 27, so add 12 months. The data could be first half 28, but Wall Street is like, okay, there's three other competitors. You've got some Chinese companies that have now gone public through a reverse merger. They're showing like north of 20, although it's small numbers. Does 20 matter versus 15? I don't know, but you tell me how should we put into context your program versus the fact that Wall Street just says there's all these other programs. I need like six, to be honest. You can correct me on the number. But I'm told there's like six. So what does this mean? We're going to split this more? We're going to six people?

So any really important drug category will draw competitors. Okay. Right? This is drug development. This is no different.

Michael Yee Other

Big market, then.

Big market. So this is a big one. And so we're leading, which is really exciting. But obviously, I think there will be people who come. And again, it's a big enough market. It can handle multiple players. But really important to be first here. And we are. So I think just building on what you asked, what you pointed out with our profile, just reminding people. So this is a one-time potential functional cure where you get an infusion for two to three hours for a disease that is affecting your lung and your liver for life and is steadily progressive. And it's incredibly debilitating. And with that one infusion, we reliably get patients from their disease where they have alpha-1 levels in the 4 to 6 range, and all of their alpha-1 is this bad protein called Z. It's a mutant form. We take them to the mid-teens on average, okay, and now over 90% of that protein is what we call M, which is the normal form of the protein, and only a little bit left is Z. So, furthermore, because we fixed the gene in its normal location in the genome, it has its on-off switch still. And so, when you get sick, your body wants to make more to protect your lungs from damage. This is how the damage happens. So, in fact, in our case, once we've corrected the gene, when you get sick, it goes on higher, and we've shown that as well. So, we have effectively done all of the things you would need to do to take a patient from a disease profile, which we understand really well, To look, just as you said, exactly like a carrier, someone who only carries one copy of the mutation, but the other copy is normal. And those folks do not have the disease by definition. So that's hence the basis for saying it's a functional cure. Now, what will competitors come to do? So our job is to bring that to patients as quickly as possible. We're racing through this 50-patient pivotal trial now. We have an alignment with the FDA that that would be submittable for an accelerated approval. In the U.S., that'll be really, really exciting. And we see tremendous demand both for our program. I think the relationships we've built in this community over the last seven years are very deep. We have a very large clinical network around the world at this point.

Speaker 2

Why do you say that? Is that a different population than hematologists?

Totally different, of course. Yeah, in fact, it's kind of a unique population. It also isn't like a liver metabolic. This lives in, there's some hepatologists who study the liver failure piece of this, and then obviously you're in kind of the COPD respiratory world.

Michael Yee Other

So why do you say seven years of experience?

Oh, because you have to meet all the key opinion leaders. And so we're open in their sites. We're open in 15 sites, six countries around the world. That's why the enrollment is going so well. So I think we've built a tremendous amount of experience, and that is showing now in the execution of the program.

Michael Yee Other

Okay.

So what are these competitors? Yeah, so the competitors. So the real question is, what can they show relative to us? And it isn't clear to me that there's much there. Okay, we have to wait and see. You mentioned trying to go higher in terms of average AT level. The one company you mentioned, Yoltec, coming out of China, they had one patient in the 20s who had a very high baseline. Every other patient we now know is in the teens. We've heard of another program that may be dosing, and I'm hearing teens as well. There's a couple more programs that haven't reached dosing of patients yet. I don't see where that results in a different profile. Okay. And we're already providing what I think is the functional cure patients are looking for. So for me, it's really all going to be about first-in-class advantage. With a product that does everything that patients need it to do. And that goes back to, we have at least a two-year lead on the competition because we were pioneers in the space. We've got the right relationships. I think we'll be able to launch this very successfully and then maintain a kind of franchise leadership position for the long term.

Speaker 2

How do you think about this indication for patients with liver disease, alpha-1-AT, versus not? Remind me which indication you're going for and which patients would be getting this.

Yes. So critically, you have patients who have problems with both their liver and their lung. Most patients have both. A few have only liver. That's pretty rare. And then some have lung just because their liver is getting worse but slower than the lung. So we will help both. That's the key to the mechanism, right? Because every edit I make, you're no longer creating that toxic Z protein to hurt the liver, and you're now cranking out the normal M protein to protect your lung. So you get a two-for-one benefit here. From an indication perspective, we will go after basically the 90% or so who are some lung pathology with or without liver. Again, the reality is all of them have some liver dysfunction, but that's the kind of core profile that we're enrolling in this cohort C, the pivotal trial.

Speaker 2

I mean, generally speaking, the people who are going to get this type of product appreciating that the good news is the alpha-1 antitrypsin market is actually fairly well understood. There are current plasma-derived products that are approved. My understanding is that these companies do north of a billion dollars in product with weekly infusions from plasma-derived donors who have to give their plasma to do this. Yes. And they're doing this weekly for the rest of their life. Yes. To try and get maybe 11 micromolar. Yeah. So and that's doing a billion dollars and it's weekly for the rest of your life.

That's correct.

Speaker 2

Now, Sanofi just did update because they have a potential monthly. I'm going to talk about a competitor. And they are going to file sometime in 27. Yep. Do you have a view about that product? I mean, you know, to be fair. People have options, right? So monthly versus that. But the market is well understood, and there are thousands and thousands of patients doing that if you multiply it out. And so they would have a potential one and done, but the market is identified. There's not having to go find these patients. But the people who are going to get gene-edited are people who are pretty sick. They've got the liver disease, I would think, and the lung disease, and they are identifiable. That's why they're injecting once a week.

Well, yeah. So this market, there's 100,000 patients in the U.S. at least. Of them, 10,000 to 15,000 are diagnosed and actively being treated. There's a big diagnosis problem, so we have to work on that to bring the rest of this market online. But of those diagnosed, there's probably 8,000, 9,000 minimum who are actively on augmentation therapy. So this is a known market that we can tap into. Obviously, for the pricing that we would consider, this is a very big market opportunity and a really important medical need. Think about that number.

Michael Yee Other

It's like 10,000 people, approximately 10,000 out of the 100,000 are getting weekly infusions.

Speaker 2

At 10,000. In the U.S. In the U.S. If you take 1,000, so 10% penetration, on a potential $1 million drug. Someone needs to fact check my math, but I think that's $10 billion TAM. So that's a pretty big market, $10 billion. Yes, and I'd say those are conservative assumptions as well. Okay. So even though it's a one and done, there's $10 billion of potent, more than $10 billion on cash flow.

Yeah, and I think it's important to then realize, I think the augmentation therapy market is, I'm glad it's there for the patients, but it is not doing everything that we want it to do. Right. First, it's incredibly life debilitating and inconvenient. It's a weekly, it's a very high infusion. That is where a three-weekly, four-weekly dose would be an improvement. But remember, with augmentation, you're doing nothing about that Z protein. So your liver is still failing. And, by the way, the Z that's circulating is probably not helping. You're still making the bad protein. You're still making the bad protein. You haven't done anything to that.

Michael Yee Other

You're just trying to infuse corrected one, but you're still making the bad one.

And furthermore, that on-off switch I mentioned is missing, right? So the infused amount of protein, you have to worry about what that trough level is. When you get sick, it's not going to change. You have as much as you put in. Whereas with us, you're going to go up. So actually, the numbers are all going to be very different. So our numbers are really a floor. And when you get like, we're in the mid teens, when you get sick, you'll be in the mid 20s. Okay, okay. With augmentation, you put in 11, it's just 11. Yeah, they're not going to make any of the credit.

Speaker 2

So you believe that the gene edit programs, including from YOL, are not meaningfully differentiated. You talked about teens, you're at 15, they're at teens, you're at least a year or more ahead, at least.

I would say at least, probably more like two.

Speaker 2

And then folks like Prime, I don't even think they're in the clinic yet. Correct, I think they have. Filed, I'd prefer you.

Michael Yee Other

But they're fairly behind. You're in a pivotal study. They have no data.

Speaker 2

And what about things like WAVE and some of those types of things? Yeah, so then you have the RNA.

So I think the augmentation just in general, I think, is not doing the full solution we need. With RNA editing, it's interesting. There you are going to be creating M. You're going to be lowering Z. It will be inducible. We know that as well. The trick there is, of course, it's still a chronic therapy. You're on it for life, and I can tell you. How often is a dose? We don't know yet. Right now in the trial, they've been doing it every few weeks, but I think we have to see what their final decision is on that. But it's going to be frequent. They are also reaching into the teens in terms of micromolar AT. The issue, the difference has been the amount of M is lower so far than what we're achieving.

Michael Yee Other

Can you clarify that? Because if we get to teens, it's M, but is not M still functional?

The M would be functional that they're creating. But let's say if they were at 13, 14, but only 60% of it is M, that would be like 8, and then the rest is still Z, right? So whereas when we have a 14 and you're at 90% M, that means 13 of it is M and only 1 is Z. So that's a difference in the composition of what we're producing.

Speaker 2

So you're saying the headline number is overstated when they're in the teens because only 60% of that's actually the functional part.

Right. What I would say is I think the headline number is one aspect, but you have to care about the composition and particularly how much M you're creating, how much Z you're reducing, I think is important. All that said, I think, again, there's room in this market for RNA editing. I think it's going to be a helpful category. You would ask the question of who gets treated with gene editing, and the answer is I actually think everybody. So, of course, you're going to go to the sick patients who need, you know, full protection. They're worried about both their lung and their liver. That's, you know, you're going to want the dual aspect of what beam provides. At the same time, at the opposite of the spectrum, you want to prevent progression, right? You want to go as early as you possibly can where patients still have their lung function before they lose it. You can't reverse that. You can't reverse that. You can probably reverse liver damage is our belief, but lung damage, once it's gone, it's gone. So you're going to want to actually go to the earlier patients and give them a one-time, you know.

Speaker 2

So, this product would come out in 2028. I would say file in 20s by the end of 27.

So I think if we get top line data, first half 27,

Michael Yee Other

finished enrollment is first half 27.

Sorry. Yeah, yeah.

Michael Yee Other

Data is first half 28 file later in 28 on the market in 29. You are first to market.

That seems reasonable. Yes, we would.

Michael Yee Other

This would be gene editing pricing.

Speaker 2

Yep. But the idea here is that these patients are well identified. The idea is in vivo, not ex vivo, like sickle cell, which has some challenges. I mean, it can take months and months and months. It's a pretty debilitating, risky procedure to get that, although it's a very transformative result. This would be in vivo, infusion. There's no mobilization. There's none of this, and you could stop taking your weekly infusions for the rest of your life. Last program in the last couple of minutes. I do want to talk about it briefly because you hosted a whole webcast about it. I listened to your webcast. GSD1A is interesting, but It is a very small number of patients, and then I start hearing about cornstarch, and I'm like, I don't know what's going on here, so.

Michael Yee Other

Reduction of cornstarch. But now this is a disease that we are, can you tell us about GSD1A?

Speaker 2

And the idea that we could get rid of cornstarch and therefore cure these patients, but obviously... This could be a functional cure. So tell us a little bit about this.

And let me tell you the story of this disease, because I actually think it's...

Speaker 2

I do think it's like when you go to the board and you're thinking about these, we know that gene editing works. You said it too, right? It's like, we know it works. So if you're picking the indications, we want to pick indications where it's a very straightforward mutation. It's a transformative cure. It's bad if you have this disease. It's bad. And therefore, people got to get on this drug.

Yes. So let me tell you the GSD1A story. But I think, as I tell you, remember, this is just really emblematic of, effectively, any liver genetic disease. Okay. There's a lot of liver genetic disease. There are. But once we've shown we can do it once here, we can do it anywhere. That's the whole point. And this gets a little bit to the FDA's regulation changes, which are going to allow us to accelerate how we bring base editing to many, many patients across many diseases. But so the GSD1A story, this is patients who are missing one enzyme, which is required to... Keep their blood sugar high when they're not eating, when they're fasting. So we all go to sleep at night. We don't die of hypoglycemia because our livers create enough glucose to keep us alive. These patients can't do that. So they're basically constantly crashing and going hypoglycemic. It takes about two and a half hours for them to drop below the critical threshold. And if they don't eat something, they can go into a coma and die. Okay, so the cornstarch is this sort of slow, digested source of sugar that keeps them alive, right? So I have to take that every three hours, including overnight. Okay, so now you have to set your alarm clock every three hours and wake up, because if you miss the alarm, you could potentially die. That means your parents also set their alarms every time to make sure you didn't sleep through your alarm.

Michael Yee Other

All right, this is primarily kids and all that?

It's for life, but, you know, from birth, you have this issue. So I had a mother tell me, she's like, I haven't slept through the night in 14 years. So it's a terrifying situation. So bottom line is, we want to cure these patients. All we need to do is open that pathway back up, right? Fix the one enzyme. And so Ultragenix has an approved product here, right? So it's accelerated approval, because they showed some amount of reduction in the cornstarch when it was needed. This is an AAV gene therapy. That was about a 44% reduction in cornstarch utilization. Okay. We have many patients in our first six that we showed across two dose cohorts who are in the 70% range reduction up to 100% reduction. We have two patients who are completely off.

Michael Yee Other

70% to 100%.

For many patients, not all. And a couple of those patients who are fully off of cornstarch, we also went to this what's called a fasting challenge. This is data I haven't even seen from Ultrogenics, where you show that at baseline, patients take three hours to go hypoglycemic. Now, after the drug, we follow them, and these two patients were completely stable. Able to maintain their blood sugar. All the way to the end of the experiment, and they still weren't hypoglycemic at 15 hours. So that is a full approvable endpoint for sure. And so we think this is already a drug. We're very excited about it. Obviously, we're going to dose-escalate one more. We want to make sure all patients get maximum exposure to make sure they get the full benefit. We'll dose an adolescent patient just to make sure we can get a PRV, a pediatric review voucher. That can help fund a lot of what we're doing. And yes, it is an ultra-rare population. It's a few hundred patients. That is nonetheless helpful to us. It's meaningful impact. But more importantly, it lays out the tracks for how we will do this again and again, to basically take a severe genetic disorder, treat and fix the mutation underlying the cause. That should lead us to expect dramatic effects. And, and a fast path to an early approval. The next place that will be relevant is PKU, right, where we're doing the same exact thing. Right now, we have a program using these new FDA platform rules, where we have three different editors that are not going to be in that part of that program. Those three editors, we think can address up to 50% of PKU, where again, we're just gonna be fixing. So what is the platform approval framework? Yeah, it basically allows us to have these multi-editor products, where in a single IND, we will have multiple different guide RNAs, multiple different mRNAs, but all be part of the same clinical trial, one package, one DLA. Even better than that, the recent guidance from the FDA says, if you want to bring on more editors, let's say we have three in there for now, A, B, and C. If you want to bring on D through M... You don't even need to do clinical trials for that. All you need to do is show me in vitro data that tells me this should be roughly as potent and as safe as the other ones. So long as it's kind of covered by the validation experiment you did in the clinic, that's all you need to do. So then we will add those into the product as well. And in fact, we think we've estimated that with 8 to 10 editors, we can get to about 80% of PKU, and we can keep going.

Michael Yee Other

Because for different mutations. Different mutations. Different mutations within the same disease.

So it really is personalized medicine.

Michael Yee Other

If there's different mutations, your gene edit would fix that one mutation. That's right. But in some cases, there could be four different mutations for the population. That's right. Okay. That's right. Fantastic. That provides some context around that. Thank you very much, Sean. We look forward to the data at ASH and continued enrollment and progress across AAT, and thank you very much.

Thank you very much. It's an exciting time.

Michael Yee Other

All right. Thank you.

Full-screen source Call document